在当下正热的胰高糖素样肽-1受体激动剂(GLP-1)药物领域,美国制药巨头辉瑞似乎缺少了一些运气。当地时间4月14日,辉瑞宣布终止口服GLP-1受体激动剂Danuglipron的研发,该药物此前被开发用于慢性体重管理。 辉瑞此前已终止口服GLP-1候选药物Lotiglipon(每日一次)的开发,目前仅剩一款口服GIPR拮抗剂处于二期临床阶段。在千亿美元减肥药市场,辉瑞要分一杯羹,尚需时日。 ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.